Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 180

Results For "cell"

2105 News Found

Thermo Fisher Scientific extends partnership with Symphogen to support biopharma
Medical Device | March 01, 2022

Thermo Fisher Scientific extends partnership with Symphogen to support biopharma

Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments


China’s NMPA accepts supplemental NDA for Carteyva
Drug Approval | February 28, 2022

China’s NMPA accepts supplemental NDA for Carteyva

The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China


BDR Pharma launches enzalutamide in 160 mg strength
Biotech | February 28, 2022

BDR Pharma launches enzalutamide in 160 mg strength

This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage


Jeffrey DeAlmeida appointed Senior VP of BASF pharma solutions
People | February 28, 2022

Jeffrey DeAlmeida appointed Senior VP of BASF pharma solutions

In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America


New data reinforces efficacy of Tezspire
Biotech | February 27, 2022

New data reinforces efficacy of Tezspire

These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting


Alps Pharma launches a new water soluble Isoquercetin
News | February 27, 2022

Alps Pharma launches a new water soluble Isoquercetin

Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.


Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


Japan approves Keytruda plus Lenvima for two types of cancer
Drug Approval | February 26, 2022

Japan approves Keytruda plus Lenvima for two types of cancer

Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.


Wockhardt Hospitals, Mira Road opens centre for sports medicine
Hospitals | February 25, 2022

Wockhardt Hospitals, Mira Road opens centre for sports medicine

The facility is spread across 215000 sq. feet and provides super-speciality care


GliaPharm SA collaborate with Wyss Centre for Alzheimer therapy
Biotech | February 25, 2022

GliaPharm SA collaborate with Wyss Centre for Alzheimer therapy

The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers